Athenex, Inc. Reports Second Quarter Ended June 30, 2020 Financial Results and Provides Corporate Update
Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track Continued momentum in building commercialization infrastructure and supply chain for Oral Paclitaxel Announced two financing agreements for up to $275 million in aggregate …